| 摘要 |
Disclosed herein are hepatitis C viral protease inhibitors of formula (I):wherein a is 0 or 1; b is 0 or 1; Y is H or C1-6 alkyl;B is H, an acyl derivative or a sulfonyl derivative;R6, when present, is C1-6 alkyl substituted with carboxyl;R5, when present, is C1-6 alkyl optionally substituted with carboxyl;R4 is C1-10 alkyl, C3-7 cycloalkyl or C4-10 (alkylcycloalkyl);R3 is C1-10 alkyl optionally substituted with carboxyl, C3-7 cycloalkyl or C4-10 (alkylcycloalkyl);R2 is CH2-R20, NH-R20, O-R20 or S-R20; wherein R20 is a saturated or unsaturated C3-7 cycloalkyl or C4-10 (alkyl cycloalkyl) being optionally mono-, di- or tri-substituted withR21, or R20 is a C6 or C10aryl, C7-16 aralkyl, Het or (lower alkyl)-Het, all optionally mono-, di- or tri-substituted with R21, wherein R21 is as defined herein;R1 is C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl, all optionally substituted with halogen; andW is hydroxy or a N-substituted amino: or W taken together with the carbonyl group to which it is bonded represents an ester group, or a pharmaceutically acceptable salt thereof.
|
